Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023...

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations...

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations...